Novel heart failure device developer VisCardia said yesterday it closed a $12.5 Series B financing round and picked up the Inovise Medical’s assets and technology rights. Technology and assets from Inovise will support the continued development of VisCardia’s proprietary implantable heart failure therapy device, the Portland, Ore.-based company said. VisCardia’s implantable heart failure system is […]